Recombinant activated factor VII in children with acute bleeding resulting from liver failure and disseminated intravascular coagulation.
Recombinant activated factor VII (rFVIIa) was given to three children with acute bleeding resulting from liver failure and disseminated intravascular coagulation. Cases I and II (girls aged 3 years and 6 years, respectively) were diagnosed with Dengue hemorrhagic fever and prolonged shock. Case III, a boy aged 9 months, underwent left lobe hepatectomy for a hepatoblastoma, during which 60% of his liver was removed. This case was complicated by myoglobinuria, liver and renal impairment and early disseminated intravascular coagulation. All three patients exhibited active bleeding. Cases I and II received rFVIIa combined with other blood component replacement, while Case III received rFVIIa as the only hemostatic agent. A bolus of 40-180 microg/kg b.w. was administered followed by 16.5-33 microg/kg b.w. per h continuous infusion. As a result, bleeding was controlled, the prothrombin time was shortened and FVII clotting activity was significantly increased. In conclusion, rFVIIa has shown some efficacy in controlling acute bleeding in children with liver failure and disseminated intravascular coagulation.
Chuansumrit
A
A
Department of Pediatrics, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. raajs@mahidol.ac.th
Chantarojanasiri
T
T
Isarangkura
P
P
Teeraratkul
S
S
Hongeng
S
S
Hathirat
P
P
D000208:Acute Disease; D001777:Blood Coagulation / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D004211:Disseminated Intravascular Coagulation / Q000150:complications*; D015942:Factor VIIa / Q000008:administration & dosage*; D005260:Female; D006470:Hemorrhage / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D007223:Infant; D017093:Liver Failure / Q000150:complications*; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage
D011994:Recombinant Proteins; D015942:Factor VIIa